NCT07463651 2026-03-11
TROPHY-15
The First Affiliated Hospital of Soochow University
Phase 3 Not yet recruiting
Clinical Trials
63 trialsNCT04039607 2026-02-19
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT01730937 2026-01-28
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03298451 2026-01-14
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT03533582 2025-12-22
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Children's Oncology Group
Phase 3 Active not recruiting
NCT03755791 2025-12-11
COSMIC-312
Exelixis
Phase 3 Active not recruiting
NCT01371981 2025-11-26
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT04709380 2025-02-26
Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Terminated
NCT02576509 2025-02-17
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
Phase 3 Completed
NCT01906216 2024-08-28
SELECT
Air Force Military Medical University, China
Phase 3 Completed
NCT02856126 2024-07-23
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT03764293 2024-02-06
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT01004978 2024-01-03
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00606866 2023-11-29
MRI
University of Chicago
Phase 3 Completed
NCT03434379 2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3 Completed
NCT06073730 2023-10-10
Viale-a
The Second Affiliated Hospital of Kunming Medical University
Phase 3 Unknown
NCT02627963 2023-07-18
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
AVEO Pharmaceuticals, Inc.
Phase 3 Completed
NCT02066181 2023-06-07
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
National Cancer Institute (NCI)
Phase 3 Completed
NCT03236649 2023-02-08
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Beijing Shenogen Biomedical Co., Ltd
Phase 3 Terminated
NCT04720716 2022-09-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Unknown
NCT00625378 2022-09-01
STEP
Bayer
Phase 3 Completed
NCT01015833 2022-08-04
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT01761266 2022-04-05
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Phase 3 Completed
NCT01887717 2021-04-21
YES-P
Boston Scientific Corporation
Phase 3 Terminated
NCT02460991 2021-02-12
SOLACE
Boston Scientific Corporation
Phase 3 Terminated
NCT04229355 2021-02-09
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 3 Unknown
NCT02562755 2020-12-16
PHOCUS
SillaJen, Inc.
Phase 3 Completed
NCT03164382 2020-12-16
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT01833299 2020-02-11
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT02867280 2020-02-11
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Sun Yat-sen University
Phase 3 Terminated
NCT02436902 2020-01-10
A-TACE/S-HCC
Guangxi Medical University
Phase 3 Unknown
NCT02774187 2019-12-05
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT04163237 2019-11-14
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
Guangxi Medical University
Phase 3 Unknown
NCT03775395 2019-01-03
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
Sun Yat-sen University
Phase 3 Unknown
NCT01234337 2018-11-06
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Bayer
Phase 3 Completed
NCT00984282 2018-09-13
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Bayer
Phase 3 Completed
NCT00692770 2018-08-08
STORM
Bayer
Phase 3 Completed
NCT01135056 2018-04-24
SIRveNIB
Singapore General Hospital
Phase 3 Unknown
NCT03468231 2018-03-16
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
Sun Yat-sen University
Phase 3 Unknown
NCT01482442 2017-01-16
SARAH
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT01223027 2015-12-07
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Novartis
Phase 3 Completed
NCT00110019 2015-10-19
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00492986 2014-12-30
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
Bayer
Phase 3 Completed
NCT00300885 2014-11-04
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Bayer
Phase 3 Terminated
NCT00105443 2014-10-31
SHARP
Bayer
Phase 3 Completed
NCT00111007 2014-10-31
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 3 Completed
NCT00111020 2014-08-06
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Bayer
Phase 3 Completed
NCT00492752 2014-04-16
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Bayer
Phase 3 Completed